Game-Changer for Melanoma: New Drug Approved for Kids 12 and Up!
MHRA Greenlights Opdualag for Young Melanoma Patients
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given the go-ahead to Opdualag (nivolumab-relatlimab), a cutting-edge melanoma treatment, for patients aged 12 and over. This is a major breakthrough for those facing advanced melanoma, a deadly skin cancer that can quickly spread across the body.
Speedy Access Through Project Orbis
Melanoma cases are on the rise in the UK, mainly caused by sun and sunbed exposure. Opdualag’s approval came via Project Orbis, an MHRA-led global initiative fast-tracking promising cancer drugs. Julian Beach, MHRA’s Interim Executive Director of Healthcare Quality and Access, said this scheme is crucial to getting lifesaving treatments to patients sooner.
How Opdualag Works and What Patients Can Expect
Opdualag is an intravenous combo of two monoclonal antibodies – nivolumab and relatlimab – that block PD-1 and LAG-3 proteins. This unleashes the body’s T cells to attack melanoma cells more effectively. Treatment lasts about 30 minutes every four weeks, under strict oncologist supervision, with length of therapy depending on patient response.
The Clinical Proof and Side Effects to Watch
The approval was backed by a large Phase 2/3 trial with 714 advanced melanoma patients. Those on Opdualag saw their disease hold off for an average of 10.1 months, more than double the 4.6 months for patients on nivolumab alone.
But it’s not without downsides. Common side effects include fatigue, muscle and joint pain, rashes, headaches, nausea, fever, cough, breathing difficulties, and thyroid changes. The MHRA urges patients to report any symptoms via their Yellow Card scheme to keep safety in check.
This approval marks a huge step forward, offering new hope to melanoma sufferers — especially youngsters — in the battle against this aggressive skin cancer.
